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Hyperuricemia induces endothelial dysfunction.
Background. Hyperuricemia has been linked to cardiovascu-
lar and renal diseases, possibly through the generation of reac-
tive oxygen species (ROS) and subsequent endothelial dysfunc-
tion. The enzymatic effect of xanthine oxidase is the production
of ROS and uric acid. Studies have shown that inhibiting xan-
thine oxidase with allopurinol can reverse endothelial dysfunc-
tion. Furthermore, rat studies have shown that hyperuricemia-
induced hypertension and vascular disease is at least partially
reversed by the supplementation of the nitric oxide synthase
(NOS) substrate, L-arginine. Therefore, we hypothesized that
uric acid induces endothelial dysfunction by inhibiting nitric
oxide production.
Methods. Hyperuricemia was induced in male Sprague-
Dawley rats with an uricase inhibitor, oxonic acid, by gavage;
control rats received vehicle. Allopurinol was placed in drink-
ing water to block hyperuricemia. Rats were randomly divided
into four groups: (1) control, (2) allopurinol only, (3) oxonic
acid only, and (4) oxonic acid + allopurinol. Rats were sacri-
ficed at 1 and 7 days, and their serum analyzed for serum uric
acid and nitrites/nitrates concentrations. The effect of uric acid
on nitric oxide production was also determined in bovine aortic
endothelial cells.
Results. Oxonic acid induced mild hyperuricemia at both 1
and 7 days (P < 0.05). Allopurinol reversed the hyperuricemia
at 7 days (P <. 001). Serum nitrites and nitrates (NOX) were
reduced in hyperuricemic rats at both 1 and 7 days (P < .001).
Allopurinol slightly reversed the decrease in NOX at 1 day and
completely at 7 days (P < .001). There was a direct linear cor-
relation between serum uric acid and NOX (R2 = 0.56) and a
trend toward higher systolic blood pressure in hyperuricemic
rats (P = NS). Uric acid was also found to inhibit both basal
and vascular endothelial growth factor (VEGF)-induced nitric
oxide production in bovine aortic endothelial cells.
Conclusion. Hyperuricemic rats have a decrease in serum
nitric oxide which is reversed by lowering uric acid levels. Sol-
uble uric acid also impairs nitric oxide generation in cultured
endothelial cells. Thus, hyperuricemia induces endothelial dys-
function; this may provide insight into a pathogenic mecha-
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nism by which uric acid may induce hypertension and vascular
disease.
Endothelial dysfunction, particularly impaired nitric
oxide production, is a common finding in patients with
cardiovascular and renal diseases and is thought to be
mediated in part by reactive oxygen species (ROS) [1].
ROS can be generated by several mechanisms, one of
which involves reaction of xanthine oxidase with xan-
thine to generate superoxide anion and uric acid. Several
studies have reported that xanthine oxidase inhibitors
such as allopurinol can reverse endothelial dysfunction
in subjects with congestive heart failure [2, 3] or type
2 diabetes mellitus [4]. These latter studies assume that
the benefit of xanthine oxidase inhibition was solely via
its ability to lower ROS; however, xanthine oxidase in-
hibitors also lower uric acid. Indeed, there is also strong
evidence linking uric acid with cardiovascular and re-
nal disease [5]. Specifically, animals made hyperuricemic
by administering an inhibitor of uricase (which happens
to also block oxidant formation) develop hypertension
and vascular disease, which is at least partially reversed
by supplementing with L-arginine, a nitric oxide syn-
thase (NOS) substrate [6]. A study in healthy volunteers
has also shown that serum uric acid inversely fluctuates
with the potent vasodilator nitric oxide during a 24-hour
period [7]. Given these findings, we hypothesized that
hyperuricemia may induce endothelial dysfunction by in-
hibiting the production of nitric oxide.
METHODS
In vivo studies
Male Sprague-Dawley rats were housed in standard
conditions and fed normal diets. We induced hyper-
uricemia with an uricase inhibitor, oxonic acid (750 mg/
kg/day), by gavage, with control rats receiving vehi-
cle. Allopurinol was used to block hyperuricemia by
placing allopurinol in the drinking water (150 mg/L).
Rats were divided into four groups: (1) control, (2)
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Fig. 1. The relationship of serum uric acid
(UA) and serum nitrites (NOX) at 1 and 7
days.
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Fig. 2. Correlation of serum uric acid (UA) and serum nitrites (NOX).
allopurinol only, (3) oxonic acid only, and (4) oxonic acid
+ allopurinol. Systolic blood pressure was measured us-
ing a tail-cuff sphygmomanometer. The amount of drink-
ing water consumed and changes in body weight were
noted. Rats were sacrificed at 1 and 7 days. Serum was
analyzed for uric acid concentration and nitrites/nitrates
(NOX) by chemiluminescence method [8]. Statistical
analysis between subgroups was performed using anal-
ysis of variance (ANOVA).
In vitro studies
Bovine aortic endothelial cells (BAEC) (passages 4
to 8) (Cambrex, East Rutherford, NJ, USA) were cul-
tured in endothelial growth media (EBM) with Bullet
Kit (Cambrex). The effect of soluble uric acid (2.5 to
7.5 mg/dL) on nitric oxide production was mea-
sured in real-time based on the fluorescence of 4,5-
diaminofluorescein (DAF-2) which binds to nitric oxide
[9]. Specifically, control BAEC and BAEC treated with
different concentrations of uric acid (2.5 to 7.5 mg/dL
for 24 hours) were first washed in Hank’s balanced salt
solution (HBSS) and then incubated with 5 lmol/L DAF-
FM diacetate (Molecular Probes, Eugene, OR, USA) for
30 minutes at 37◦ C in darkness. After the incubation,
BAEC were washed to remove excess probe. Fresh HBSS
containing 100 lmol/L L-arginine (a substrate for nitric
oxide synthesis) was added to cells, and cells were in-
cubated for an additional 10 minutes to allow complete
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Fig. 3. Effects of uric acid (UA) on nitric oxide production by bovine
aortic endothelial cells (BAEC). Cultured BAEC growing on 30 mm
dishes with a glass bottom were treated with 2.5 to 7.5 mg/dL uric
acid in RPMI culture media without serum for 24 hours. Visualiza-
tion of nitric oxide (NOO production using a fluorescent probe 4,5-
diaminofluorescein (DAF-FM) has been done as described in the Meth-
ods section. (A) Intensity of DAF fluorescence inside four control cells
and four cells treated with uric acid (2.5, 5.0, or 7.5 mg/dL) was quan-
tified every 5 minutes for 20 minutes. Intensity at the 0 point time was
taken as a background and all measurements were corrected by sub-
tracting background fluorescence. Each point represents an average
DAF fluorescence in one cell+/−SD. All changes in nitric oxide produc-
tion in BAEC treated with 5.0 and 7.5 mg/dL uric acid were significant
compared with control BAEC with P < 0.05 (an unpaired, two-tailed
Student t test). (B) DAF fluorescence images of control (A1 and A2)
BAEC and BAEC treated with 7.5 mg/dL uric acid (B1 and B2). The
images of fluorescence were made just after the procedure of DAF-FM
de-esterification (the 0 time point; see the Methods section) (A1 and
B1) and after the 20-minute period of measurements (A2 and B2).
de-esterification of the intracellular diacetate. After this
procedure, direct visualization of nitric oxide production
with the fluorescent indicator was performed using a laser
scanning confocal microscope with excitation and emis-
sion maxima at 495 and 515 nm, respectively. Intensity of
fluorescence was quantified using LSM 510 (version 3.0
SP3) software for the Carl Zeiss Laser Scanning Micro-
scope (Carl Zeiss, Inc.).
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Fig. 3. (continued)
The amount of nitric oxide released into the cell media
was also measured in the gas phase using a standard-
ized Seivers NOA 280 chemiluminescence analyzer (An-
alytix, Durham, UK), after cells were stimulated with vas-
cular endothelial growth factor (VEGF165) (50 ng/mL)
in EBM with 5% serum for 24 hours. Results are cor-
rected for background levels of nitric oxide present in
culture medium alone, and are expressed as nanomol per
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microgram (nitric oxide/total protein) and as a mean ±
SEM of three independent experiments performed in
triplicate determinations.
RESULTS
There was no difference in the amount of water con-
sumed and the change in body weight between the three
groups over seven days. Oxonic acid induced a mild hy-
peruricemia at both 1 day (1.7 ± 0.7 vs. 0.8 ± 0.4 mg/dL
in oxonic acid vs. control) (P < 0.05) and 7 days (1.8 ±
0.4 vs. 0.9 ± 0.7 mg/dL in oxonic acid vs. control) (P <
0.05). Allopurinol only had a mild and nonsignificant ef-
fect on serum uric acid concentrations at day 1 (1.52 ±
0.3 mg/dL) (P = NS), but effectively reversed the hyper-
uricemia at 7 days (0.3 ± 0.2 mg/dL) (P < 0.001). Serum
nitrites and nitrates (NOX) were reduced by 40% to 50%
in hyperuricemic rats at both 1 day (15.6 ± 0.4 vs. 22.6 ±
1.0 lmol/L in oxonic acid vs. control) (P < .001) and 7 days
(14.6 ± 1.1 vs. 27.5 ± 1.3 lmol/L in oxonic acid vs. control)
(P < .001). This decrease in NOX was improved slightly
by allpurinol at 1 day (17.4 ± 0.8 lmol/L) (P < .001)
and reversed completely at 7 days (25.0 ± 0.8 lmol/L)
(P < 0.001) (Fig. 1). There was also a direct linear cor-
relation between serum uric acid and NOX (Fig. 2). Rats
treated with allopurinol alone did not show a significant
change in either serum uric acid or NOX concentration.
Rats treated with oxonic acid also showed a trend toward
higher systolic blood pressure at 7 days (178 ± 18 vs. 158 ±
16 vs. 147 ± 11 mm Hg in oxonic acid vs. control vs. oxonic
acid/allopurinol) (P = NS).
Additional studies were performed to determine if
uric acid affected nitric oxide production in cultured en-
dothelial cells. Uric acid dose-dependently inhibited ni-
tric oxide production (Fig. 3A and B) as measured by
DAF-FM fluorescence; uric acid (5 mg/dL) also blocked
VEGF-induced nitric oxide release into the culture media
(Fig. 3C).
CONCLUSION
Most mammals have the enzyme uricase that degrades
uric acid to allantoin with the generation of oxidants.
In humans, uricase is mutated resulting in higher uric
acid levels. Rats administered an uricase inhibitor (oxonic
acid) develop mild hyperuricemia, hypertension, and vas-
cular disease that is mediated by activation of the renin-
angiotensin system, a loss of macula densa NOS, and the
development of microvascular disease [6]. In this study
we also demonstrate that hyperuricemic rats have a fall in
serum nitrites (a reflection of nitric oxide production) that
is reversed by allopurinol. Furthermore, there was a di-
rect linear correlation between serum uric acid and serum
nitric oxide. The induction of hyperuricemia also showed
a trend toward increased systolic blood pressure. In ad-
dition, we found that uric acid also impaired both basal
and VEGF-induced nitric oxide production in cultured
endothelial cells. This data suggest that hyperuricemia
may cause endothelial dysfunction. Interestingly, Waring
et al [10] recently reported that the infusion of uric acid
into humans does not impair endothelial function over
a 1-hour period. However, these studies did not mea-
sure nitric oxide levels nor mention effects of sustained
hyperuricemia on endothelial-dependent vasodilatation.
These discrepancies can also be explained by differences
in methods and species, suggesting the need for further
studies to dissect out the complex relationship of uric acid
to endothelial function and cardiovascular disease.
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